Sells wearable medical devices that deliver Tumor Treating Fields therapy to patients with glioblastoma, lung cancer and pancreatic cancer.
10-K for FY2025, filed Feb 26, 2026We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric…View ↗
Optune Gio is approved by the U.S. Food and Drug Administration ("FDA") under the Premarket Approval ("PMA") pathway for the treatment of…View ↗
Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic NSCLC concurrent with…View ↗
Optune Pax is approved by the FDA under the PMA pathway for the treatment of adult patients with locally advanced pancreatic cancer…View ↗
TTFields therapy is delivered through a portable medical device. The complete device, called Optune Gio (for the treatment of GBM), Optune…View ↗
Patients use NovoCure’s products in active markets; the company has coverage policies with public and private payers for Optune Gio and seeks case-by-case reimbursement for Optune Lua and Optune Pax where broader coverage is being pursued. Zai Lab has a license to commercialize the products in Greater China.
10-K for FY2025, filed Feb 26, 2026We market our Products in multiple countries around the globe with the majority of our revenues coming from the use of Optune Gio in the…View ↗
We have established coverage policies with both public and private payers for the use of Optune Gio in our active markets. We are actively…View ↗
In 2018, we granted Zai Lab (Shanghai) Co., Ltd. ("Zai") a license to commercialize our Products in China, Hong Kong, Macau and Taiwan…View ↗
Our revenues are primarily derived from patients using our Products in our active markets. We charge for treatment with our Products on a…View ↗
10-Q for Q3 FY2026, filed Oct 29, 2026
−$10.4MView ↗
8-K, filed Nov 9, 2026
On November 9, 2026, NovoCure Limited (“Novocure”) issued a press release announcing that it has received a Not Approvable Letter from the…View ↗
8-K, filed Oct 29, 2026
Strong performance drove increased net revenue guidance for full-year 2026 to $736 million - $743 million and adjusted EBITDA guidance to…View ↗
8-K, filed Oct 1, 2026
On September 15, 2026, the Company issued a press release announcing that that Japan’s Ministry of Health, Labour and Welfare (MHLW)…View ↗
8-K, filed Jun 30, 2026
On June 30, 2026, the Company issued a press release announcing that that that Optune Pax® has received a CE (Conformité Européenne) Mark…View ↗
More cancer uses
The latest report describes Optune Lua for non-small cell lung cancer and Optune Pax for pancreatic cancer; the older report described Optune Lua for mesothelioma and reported lung cancer as a clinical-study area.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026
Loading...